CVS Health Stock Surged On An Aetna Recovery That Management Had Already Sized

The company published the arithmetic of its own margin repair, and the first hard proof landed a quarter before the shares started compounding.

CVS Health (CVS) stock has climbed 73% over the past year, from $60.38 to $104.43, against 18.7% for the S&P 500. The group did not move as one: UNH gained 60% and ELV 31%, while CI fell 4.2%. If you watched it run without owning it, the question is not what happened at the top, but what was sitting in the public record before the price responded.

Aetna Stopped Being The Drag

The company puts its fiscal Q1 2026 improvement primarily on Health Care Benefits, the Aetna insurance business. Segment adjusted operating income was about $3 billion on a medical benefit ratio of 85%, against 87% in fiscal Q1 2025, and Aetna contributed over $1 billion of year-over-year improvement. Enterprise adjusted operating income of about $5.2 billion rose more than 12% and adjusted earnings of $2.57 a share rose over 14%, on revenue above $100 billion that grew over 6%. Its two non-insurance segments went the other way, with adjusted operating income down about 7% at Health Services and about 9% at Pharmacy and Consumer Wellness. Full-year 2026 adjusted earnings guidance moved to $7.30 to $7.50 from $7 to $7.20. So the shape of the recovery is clear enough: insurance margin coming back, with the other two segments giving some of it away.

Management Sized The Aetna Prize While It Was Still Losing Money

That recovery was no discovery. At its fiscal Q3 2024 results, Health Care Benefits posted an adjusted operating loss of $924 million on a medical benefit ratio of 95%, and management warned the segment might show operating losses for full-year 2024 after earning over $5.5 billion of adjusted operating income in 2023. It then did the arithmetic out loud: restoring Aetna to 2023 profitability was worth well over $3 of embedded adjusted earnings per share. By the fiscal Q4 2024 report it had published the conversion rate too: roughly $0.75 of adjusted earnings per share for each point of Health Care Benefits margin, and about $800 million of segment adjusted operating income for each point of medical cost trend. Medicare Advantage margins had ended 2024 between negative 4.5% and negative 5%, against a 3% to 5% target. That was the promise, and only the promise.

Fiscal Q1 2025 Is Where The Promise Became Results

The fiscal Q1 2025 report, the last one public before the run began, is where the swing actually landed: Health Care Benefits adjusted operating income of about $2 billion, up over $1.2 billion from a year earlier, on a medical benefit ratio of 87%, down 310 basis points. Full-year 2025 adjusted earnings guidance went up to $6 to $6.20 from $5.75 to $6, and the company committed to exiting the individual exchange business in 2026, a book then projected to lose $350 million to $400 million across 2025. The base was visibly depressed: revenue over the trailing twelve months was $378.96 billion, up 5.0% year over year, against a three-year average of 8.1%, with net margin at 1.4% against a three-year peak of 2.7%. The evidence was public. Whether it was usable is another question.

Legible In The Transcripts, Invisible On The Tape

Legible, but quiet. The pre-surge news flow was housekeeping: a dividend declaration, an earnings-date notice, two community workforce centers and a store reopening. Options pricing was equally unbothered, with implied volatility in the 24th percentile of its trailing one-year range in mid-June 2025 and the 19th percentile a month later, at a reading of 28.0. A high percentile would mean traders were braced for a large move in either direction; a low one, that they were braced for nothing. The measured window then opens in late July 2025, one day before a scheduled fiscal Q2 2025 report. So the verdict: the signs were real and specific, but they lived in segment margin lines and guidance ranges rather than in price action, so patience was the edge. What to watch for next is a company raising its outlook while the price has only started to follow, which is what a screen for names where a rising outlook meets price momentum is built to surface.

Catching One Turnaround Is Not A Method

Reading this one right meant sitting through several quarters of published but unpaid progress, a hard skill to repeat on demand. Doing it across enough names that one misread costs you little is a different job. That is the case for a rules-based portfolio: the Trefis High Quality Portfolio buys quality on fixed rules, so being right about any one company never has to carry the result. That portfolio has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.